Prior working score88Below the 100+ stock-sleeve gate.
Portfolio roleResearchNot a third stock candidate today.
Next catalystFull re-scoreQ2 release reviewed; filing, leadership and valuation checks remain.
Why It Is Interesting
- Automation categoryUiPath is a direct automation platform rather than another AI infrastructure supplier, so it diversifies the research map.
- Q2 FY2027 updateRevenue was USD 410mn, up 13% year over year; ARR was USD 1.938bn, up 12%.
- Retention signalDollar-based net retention stayed at 109%, useful but still not obviously elite for a concentrated stock sleeve.
- Cash generationQ2 GAAP operating income was USD 32mn; operating cash flow and adjusted FCF were each about USD 31mn.
- Balance sheet supportCash, cash equivalents, and marketable securities were USD 1.405bn at quarter-end.
Why It Is Not Buyable
- Below 100+The 10/10 system forbids a third stock without a completed 100+ score and a better case than GOOGL or TSM.
- Growth question12% ARR growth and 109% DBNRR do not look strong enough yet for a concentrated stock sleeve.
- AI platform riskMicrosoft, Salesforce, ServiceNow, and other workflow platforms may bundle agentic automation into existing enterprise suites.
- Quality adjustmentsSBC, non-GAAP adjustments, buyback economics, and GAAP profitability quality need a full note.
Strategy Impact
PATH retains its prior 88/125 working score pending full post-Q2 review. It does not change the active 60% SXR8, 20% GOOGL, 20% TSM allocation, and it does not outrank VRT, ARM, or MU in the current AI infrastructure research queue.
Score Gate Before Any Buy
| Check | Requirement |
|---|---|
| Post-Q2 review | Full filing, leadership changes, durability, SBC/buybacks and valuation; no demonstrated ARR/retention acceleration. |
| AI durability | Evidence that agentic automation expands demand instead of being absorbed by larger platforms. |
| Competition | Compare against Microsoft, Salesforce, ServiceNow, and internal enterprise workflows. |
| Valuation | Full 5-20 year return case after price, dilution, SBC, and buybacks. |